GlobeNewswire Inc | Jan 5, 2021 09:00AM EST

January 05, 2021

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the companys presentation at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:50 a.m. ET.

The live webcast will be accessible under Events and Presentations in the Investors section of the company's website. This archived webcast will be available on the Adverum website following the presentation for 30 days.

About Adverum BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.

Investor Relations ContactMyesha LacyVice President, Investor Relations and Corporate CommunicationsAdverum Biotechnologies, Inc.T: 650-649-1257E: mlacy@adverum.com

Media ContactAndrea CohenSam Brown Inc.T: 917-209-7163E: andreacohen@sambrown.com